AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates (MTEM), Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery ...
Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, “MT-6402 and MT-8421 represent novel approaches to validated immuno-oncology targets. Monotherapy activity with MT-6402 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback